Price$0.76-0.01 (-1.41%)
02:30 PM07:45 PM
News · 26 weeks57-69%
2025-12-142026-06-07
Mix4190d
- SEC Filings16(39%)
- Insider12(29%)
- Other6(15%)
- Earnings5(12%)
- Offering1(2%)
- Leadership1(2%)
Latest news
25 items- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron to Present at BIO International Convention 2026Company will highlight new and recently published data for stem cell therapy laromsestrocel Focus on potential partnership and strategic opportunities for Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric Dilated Cardiomyopathy and Aging-related FrailtyCorporate presentation Wednesday, June 24th at 2:15pm PT in Theater 4 MIAMI, June 04, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will participate in the BIO International Convention taking place June 22-25, 2026 at the San Diego Convention Ce
- SECSEC Form DEFA14A filed by Longeveron Inc.DEFA14A - Longeveron Inc. (0001721484) (Filer)
- SECSEC Form DEF 14A filed by Longeveron Inc.DEF 14A - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key PrioritiesMIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company's Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join Longeveron at what I believe is an extraordinary time for the Company and our stem cell therapy, laromestrocel (Lomecel-B®). Longeveron is progressing through a significant inflection point in the Company's history. After taking on the CEO role in February, we embarked on two immediate critical task
- SECSEC Form SCHEDULE 13G filed by Longeveron Inc.SCHEDULE 13G - Longeveron Inc. (0001721484) (Subject)
- SECLongeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces 2026 First Quarter Financial Results and Provides Business UpdateOn track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic agi
- SECSEC Form 10-Q filed by Longeveron Inc.10-Q - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationDMC performed a risk-benefit assessment, identified no new safety concerns, and recommended continuation of the study as designed through completionThis review represents the final planned independent safety assessment prior to completion of the trialELPIS II top-line trial results anticipated in August 2026 MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announce
- SECLongeveron Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that a constructive Type C meeting with the U.S. Food and Drug Administration (FDA or Agency) was held in late March, with the FDA providing their meeting summary in late April, to discuss the ongoing development of laromestrocel (LOMECEL-B®), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (ELPIS II) for hypoplastic left heart syndrome (HLHS). Top-line results from the randomized,
- INSIDERCTO & SVP of CMC Blass Devin was granted 250,000 shares, increasing direct ownership by 131% to 441,543 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERChief Executive Officer Willard Stephen H was granted 500,000 shares, increasing direct ownership by 173% to 789,727 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERChief Medical Officer Agafonova Nataliya was granted 250,000 shares, increasing direct ownership by 123% to 453,419 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERGeneral Counsel, Secretary Lehr Paul T was granted 250,000 shares, increasing direct ownership by 74% to 588,566 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERChief Financial Officer Locklear Lisa was granted 250,000 shares, increasing direct ownership by 116% to 465,686 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- SECSEC Form PRE 14A filed by Longeveron Inc.PRE 14A - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13759888 Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" se
- PRThe Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
- SECSEC Form EFFECT filed by Longeveron Inc.EFFECT - Longeveron Inc. (0001721484) (Filer)
- SECSEC Form 424B3 filed by Longeveron Inc.424B3 - Longeveron Inc. (0001721484) (Filer)
- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- SECSEC Form S-1 filed by Longeveron Inc.S-1 - Longeveron Inc. (0001721484) (Filer)
- PRBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsAVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB:AVAI), Lineage Cell Therapeutics, Inc. (NYSE:LCTX), Ocugen, Inc. (NASDAQ:OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Longeveron Inc. (NASDAQ:LGVN)Key Takeaways:Avaí Bio (OTCQB:AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will present their latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely recognized for discovering the Klotho gene [1
LGVN FAQ
7 questionsWhat does Longeveron Inc. do?
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was...Where does LGVN stock trade?
Longeveron Inc. (LGVN) is listed on NASDAQ.What sector and industry is LGVN in?
Longeveron Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Longeveron Inc. go public?
Longeveron Inc. (LGVN) completed its IPO in 2021.What are analysts saying about LGVN?
Longeveron Inc. has had 2 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1000.00 price target on 2024-12-06. Recent price targets range from $1000.00 to $2000.00.What companies are similar to LGVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LGVN side-by-side with any of them on Quantisnow.How can I track LGVN on Quantisnow?
Quantisnow aggregates Longeveron Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGVN to receive live email and push alerts on every new disclosure.